{"name":"Ming Hou","slug":"ming-hou","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE10WHQ4T081R1k3OUxDeUhlZlpNa3JTTTJkRU9CdktQd2h3RklibU94TWlKN285Q01lMFFUX3J5WlVWQWg4eTBLLXRaV0diaFBOcTk3THRPQ1dueFNwd0tLVlFlUTI0QXQzOXdKYw?oc=5","date":"2024-03-28","type":"trial","source":"Wiley Online Library","summary":"A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia - Wiley Online Library","headline":"A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary im","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPY0c5LXJuNVFTbHpEWFlzb3Atb1FqQkIyUjdMOFpwX3VXZlRkT0ZhY1VpUTV0MzdmX3BHdjVmelNzRFk3aUZGLWpPZnVPT2praHVXWkhxUkxkdnE4SGlFNG8tR2xqeFd1N2dBWm9fYW1wYWk4R25GdkJqZnhFMmRtTEYtS2VTMm4wSFJzMmpBXzUwMzA?oc=5","date":"2022-10-17","type":"pipeline","source":"Frontiers","summary":"The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors - Frontiers","headline":"The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1BbGZKa3Z1UEU5TGItaHNnenB4T0ZwajVxZUhYY2VHa1NjUXBJN0IxbWJ2cnVQSWtZUlpzSUVHczluU1d2cWJFT1FuSmtxOWc3SndPdWIyMk9EYnJWSWdSdXI5Z2htd1I5?oc=5","date":"2020-11-10","type":"regulatory","source":"Wiley Online Library","summary":"American Journal of Hematology | Blood Research Journal - Wiley Online Library","headline":"American Journal of Hematology | Blood Research Journal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}